Aeolus Pharmaceuticals was previously known as Incara Pharmaceuticals which was incorporated in 1994. Incara Pharmaceuticals changed its name to Aeolus Pharmaceuticals effective July 16, 2004. The record date for the company's reverse split of stock was the close of business on July 15, 2004. Common stock began trading on a split-adjusted basis as of July 16, 2004 under the symbol AOLS. Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds, referred to as manganoporphyrins, for diseases and disorders of the central nervous system, respiratory systems, autoimmune systems and oncology.